What's Happening?
A webinar scheduled for May 27, 2026, will focus on accelerating Antibody-Drug Conjugate (ADC) development through efficient cell culture process optimization. Hosted virtually, the session will cover key considerations for upstream cell culture process development,
robust scale-up, and process characterization. Practical case studies from AsymBio’s Upstream Process Development Platform will be presented, illustrating how optimizing process parameters can enhance intermediate quality and yield. The event aims to support the transition from early-stage development to commercial production, emphasizing the importance of efficient antibody development and large-scale production in ADC projects.
Why It's Important?
The development of ADCs is crucial in the pharmaceutical industry, particularly for targeted cancer therapies. Efficient process development and scale-up are vital for reducing time-to-market and ensuring product quality. This webinar provides valuable insights for researchers and developers in the biopharmaceutical sector, potentially leading to advancements in ADC production. By focusing on process optimization, the event highlights the importance of innovation in bioprocessing, which can lead to cost savings and improved therapeutic outcomes. The knowledge shared could influence future ADC projects and contribute to the industry's growth.
